axiebet88 free 78 download
DePaul cruises to win over Loyola Maryland
United Airlines is one of the first major airlines to adopt one of Apple’s new features, integrating the AirTag Share Item Location feature. Apple announced a new iOS 18.2 feature in November, one that would allow uses to share the location of an AirTag via a secure link. The implications and potential applications of the feature are myriad, with tracking lost luggage being one of the prime options. The company described the feature in a November press release. Apple has introduced Share Item Location, a new iOS feature that helps users locate and recover misplaced items by easily and securely sharing the location of an AirTag or Find My network accessory with third parties such as airlines. Share Item Location is available now in most regions worldwide as part of the public beta of iOS 18.2, which will soon be available to all users as a free software update for iPhone Xs and later. Find My is built with privacy and safety at its core. The shared location will be disabled as soon as a user is reunited with their item, can be stopped by the owner at any time, and will automatically expire after seven days. “Find My is an essential tool for users around the world to keep track of and find their belongings,” , Apple’s senior vice president of Services. “The Find My network and AirTag have proven to be a powerful combination for users while traveling, providing invaluable location information when bags have been misplaced or mishandled. With Share Item Location, we’re excited to give users a new way to easily share this information directly with third parties like airlines, all while protecting their privacy.” United Integrates the Feature Barely a month later, United has become one of the first airlines to adopt the new feature, counting on it to help drive improved customer service. United today announces the integration of Apple’s new Share Item Location feature for AirTag into its mobile app, a move that’s expected to drive a much-improved customer service experience for the fewer than 1% of customers whose bags arrive on a later flight. The airline says the feature will help it better serve customers in those rare instances where things don’t go as planned. While more than 99% of customer bags flew with – or even beat – their owner to their destination so far this year, this new digital innovation is the latest example of United’s infrastructure, training and technology investments geared towards making travel easier and bag handling more seamless, especially when plans don’t go as expected. “For years, every customer has been able to track the journey of their bag through the United app as it is scanned on and off the plane, and previously, they didn’t have a way to directly share their AirTag information with our baggage team,” , United’s Chief Customer Officer. “Now, Apple’s new Share Item Location feature will help customers travel with even more confidence, knowing they have another way to access to their bag’s precise location with AirTag or their Find My accessory of choice. They can easily and securely share that with us in the United app, and our team can use the location information to find the bag and get it reunited with its owner much more quickly.” United outlined how the feature will work. It’s good to see United adopting such a useful feature. Hopefully other airlines will follow suit quickly.
Expanded CFP field draws more bets and on more teamsJulian Reese delivered 23 points and 11 rebounds as sluggish Maryland pulled away late in a 81-66 victory over Maryland Eastern Shore on Saturday in College Park, Md. Derik Queen provided 18 points and 14 rebounds while Ja'Kobi Gillespie added nine points and as many assists as the Terrapins (11-2) improved to 19-0 all-time against the Hawks, with all of the wins coming by double-digit margins. In the final nonconference game for both teams, the Terrapins' Selton Miguel had 10 points and Jordan Geronimo added nine off the bench. Playing for the first time in seven days, Maryland never trailed but struggled to pull away from UMES (4-12). Ketron Shaw paced Maryland Eastern Shore with 20 points and nine rebounds. Evan Johnson scored 15 points and Christopher Flippin added 14 points and six boards for the Hawks of the Mid-Eastern Athletic Conference, who are 0-12 against Division I schools this year. UMES kept in close in the first half as Maryland missed its first eight shots from 3-point range. The Terps held a 19-17 lead when Rodney Rice ended the drought with a corner 3 with 6:38 left in the half. About a minute later, Geronimo drained another from the same spot on the floor. In the final 53 seconds of the period, Reese wheeled inside for a three-point play, then DeShawn Harris-Smith added a buzzer-beating trey from the top of the key as Maryland took a 40-24 lead at the break. In the second half, the Hawks kept it close as Shaw continued to score in the open floor and Johnson drained a pair of 3-pointers. When Flippin made a pair of free throws with 10:08 left, he cut the Terrapins' lead to 54-48. But that's as close as the Hawks got as Maryland answered with three quick baskets. In the final 8:11, Gillespie and Miguel made 3-pointers and the duo combined on a fast break, with Gillespie feeding Miguel for a 3-point play that gave the Terrapins their biggest lead, 81-58, with 2:26 left. --Field Level Media// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC , Dec. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys " or the " Company ") is pleased to announce that it has closed the first tranche (the " First Tranche ") of its previously announced non-brokered private placement (the " Private Placement ") with the issuance of 2,200,000 units (the " Units ") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000 . Each Unit consist of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a " Warrant "), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until December 13, 2026 , being the date that is 24 months from the date of issue. The Company intends to use the net proceeds of the First Tranche for working capital. No finder's fees were paid in connection with the First Tranche. All securities issued pursuant to the First Tranche are subject to a statutory hold period expiring April 14, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation In addition, the Company announces that it has entered into a debt settlement agreement with an arm's-length consultant of the Company to settle an aggregate of $500,000 in debt owed to the consultant by issuing 5,000,000 Shares at a deemed price of $0.10 per Share (the " Debt Settlement "). The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debt through the issuance of Shares in order to preserve the Company's cash for working capital purposes. All securities proposed to be issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation. Closing of the Debt Settlement is conditional upon a number of conditions, including receipt of all applicable corporate and regulatory approvals, including the acceptance of the Canadian Securities Exchange. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933 , as amended (the " U.S. Securities Act "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPXTM immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPXTM is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin " James Passin , Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements Regarding Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements ") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, the statements relating to the Private Placement and the Debt Settlement, including the expected use of proceeds from the Private Placement and related issuance of the Shares for the Debt Settlement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the impact of any changes that may affect the anticipated use of proceeds from the Private Placement and the ability of the Company to obtain the necessary approvals to proceed with the Debt Settlement. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy of this release. Logo - https://mma.prnewswire.com/media/2415135/5078410/BioVaxys_Technology_Corp_Logo.jpg SOURCE BioVaxys Technology Corp.